Nemes Rush Group
TGTX icon

Nemes Rush Group’s TG Therapeutics TGTX Stock Holding History

Nemes Rush Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$112K Hold
2,000
– – 0.01% 262
2026
Q2 		$110K Sell
2,000
-19
-0.9% -$778 0.01% 278
2026
Q1 		$67.1K Hold
2,019
– – 0.01% 313
2025
Q4 		$60.2K Hold
2,019
– – 0.01% 324
2025
Q3 		$72.9K Hold
2,019
– – 0.01% 284
2025
Q2 		$72.7K Hold
2,019
– – 0.01% 279
2025
Q1 		$79.6K Buy
2,019
+19
+1% +$639 0.01% 273
2024
Q4 		$60.2K Hold
2,000
– – 0.01% 284
2024
Q3 		$30.4K Hold
2,000
– – ﹤0.01% 310
2024
Q2 		$35.6K Hold
2,000
– – ﹤0.01% 294
2024
Q1 		$30.4K Hold
2,000
– – ﹤0.01% 337
2023
Q4 		$34.2K Hold
2,000
– – 0.01% 304
2023
Q3 		$16.7K Hold
2,000
– – ﹤0.01% 352
2023
Q2 		$49.7K Buy
+2,000
New +$51.7K 0.01% 264

Other funds holding TGTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Nemes Rush Group's TGTX Position: Q3 2026 in Review

Nemes Rush Group held its TG Therapeutics (TGTX) position steady in Q3 2026 at 2,000 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #262.

Nemes Rush Group first reported a position in TGTX in Q2 2023 and has held it in 14 quarters since. 197 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Nemes Rush Group held 2,000 shares of TG Therapeutics worth $112K as of Q3 2026.
  • Nemes Rush Group left its TG Therapeutics share count unchanged in Q3 2026.
  • TG Therapeutics made up 0.01% of Nemes Rush Group's portfolio in Q3 2026, its #262 holding.
  • Nemes Rush Group first reported a position in TG Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • 197 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.